Paul Tudor Jones Xeris Biopharma Holdings, Inc. Transaction History

Tudor Investment Corp Et Al

$29 Billion
Q1 2025

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 225,186 shares of XERS stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

225,186

Previous 305,186 26.21%

Holding current value

$1.11 Million

Previous $1.03 Million 19.54%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$3.2 - $5.95 $256,000 - $476,000	-80,000 Reduced 26.21%	225,186 $1.24 Million
Q4 2024 Feb 14, 2025	SELL	$2.78 - $3.73 $562,035 - $754,097	-202,171 Reduced 39.85%	305,186 $1.03 Million
Q3 2024 Nov 14, 2024	SELL	$2.06 - $2.96 $135,607 - $194,853	-65,829 Reduced 11.48%	507,357 $1.45 Million
Q1 2024 May 15, 2024	BUY	$2.04 - $3.22 $40,341 - $63,675	19,775 Added 3.57%	573,186 $1.27 Million
Q4 2023 Feb 14, 2024	SELL	$1.47 - $2.36 $129,487 - $207,885	-88,087 Reduced 13.73%	553,411 $1.3 Million
Q3 2023 Nov 15, 2023	SELL	$1.8 - $2.69 $390,443 - $583,495	-216,913 Reduced 25.27%	641,498 $1.19 Million
Q2 2023 Aug 14, 2023	SELL	$1.82 - $2.98 $185,094 - $303,066	-101,700 Reduced 10.59%	858,411 $2.25 Million
Q2 2022 Aug 15, 2022	SELL	$1.48 - $2.64 $1,599 - $2,853	-1,081 Reduced 0.11%	960,111 $1.48 Million
Q1 2022 May 16, 2022	BUY	$2.0 - $2.87 $2,162 - $3,102	1,081 Added 0.11%	961,192 $2.46 Million
Q4 2021 Feb 14, 2022	BUY	$1.8 - $2.93 $1.73 Million - $2.81 Million	960,111 New	960,111 $2.81 Million

Others Institutions Holding XERS

# of Institutions

204

Shares Held

84.7M

Call Options Held

132K

Put Options Held

69.4K

View Full List

About Xeris Biopharma Holdings, Inc.

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $672M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

More about XERS

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account